Chronic Kidney Disease Clinical Trial
— RADDIOfficial title:
A Randomized, Controlled Trial to Evaluate Routine and Deferred Dialysis Initiation in Chinese Population
Verified date | April 2019 |
Source | Peking University People's Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study evaluates the efficacy and safety of deferred dialysis initiation in Chinese population. 16 tertiary hospitals across China will be randomly assigned into routine and deferred dialysis groups.
Status | Active, not recruiting |
Enrollment | 1049 |
Est. completion date | December 2020 |
Est. primary completion date | August 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility |
Inclusion Criteria: 1. Nondialysis-dependent stable CKD stage 4-5 patients (eGFR>7ml/min /1.73 m2) 2. Willing to choose dialysis as his renal replacement therapy method 3. Heart function: grade I or II (NYHA Functional Classification) Exclusion Criteria: 1. The life expectancy of patients is estimated to be short (due to causes other than kidney disease); 2. Acute infection occurred in one month; 3. Myocardial infarction, NYHA class IV or stroke events within 3 months; 4. Uncontrolled malignancy; 5. Active viral hepatitis; 6. Active rheumatic disease; 7. Pregnant women, women intending to conceive after enrollment or breastfeeding woman; 8. Planning to take kidney transplantation within the study period; 9. With indices of emergency dialysis; 10. eGFR less than 7 ml/min/1.73m2 in first visit; 11. Under other clinical studies which has an impact on this study; 12. Unable to provide written informed consent. |
Country | Name | City | State |
---|---|---|---|
China | Peking University People's Hospital | Beijing | Beijing |
Lead Sponsor | Collaborator |
---|---|
Peking University People's Hospital | Beijing Haidian Hospital/Beijing Haidian Section of Peking University Third Hospital, Beijing Hospital, National Center of Gerontology, Beijing Tongren Hospital, First Affiliated Hospital of Zhejiang University, First Hospital of China Medical University, Hangzhou Hospital of Traditional Chinese Medicine, Peking Union Medical College Hospital, Peking University First Hospital, Ruijin Hospital Affiliated to Shanghai Jiao Tong University, Shaanxi Hospital of Traditional Chinese Medicine, Shengjing Hospital, Sichuan Academy of Medical Sciences, The First Affiliated Hospital of BaoTou Medical College, The First Affiliated Hospital of Zhengzhou University, Xuanwu Hospital, Beijing |
China,
Cooper BA, Branley P, Bulfone L, Collins JF, Craig JC, Fraenkel MB, Harris A, Johnson DW, Kesselhut J, Li JJ, Luxton G, Pilmore A, Tiller DJ, Harris DC, Pollock CA; IDEAL Study. A randomized, controlled trial of early versus late initiation of dialysis. N — View Citation
Crews DC, Scialla JJ, Boulware LE, Navaneethan SD, Nally JV Jr, Liu X, Arrigain S, Schold JD, Ephraim PL, Jolly SE, Sozio SM, Michels WM, Miskulin DC, Tangri N, Shafi T, Wu AW, Bandeen-Roche K; DEcIDE Network Patient Outcomes in End Stage Renal Disease St — View Citation
Nesrallah GE, Mustafa RA, Clark WF, Bass A, Barnieh L, Hemmelgarn BR, Klarenbach S, Quinn RR, Hiremath S, Ravani P, Sood MM, Moist LM; Canadian Society of Nephrology. Canadian Society of Nephrology 2014 clinical practice guideline for timing the initiatio — View Citation
Rosansky SJ, Cancarini G, Clark WF, Eggers P, Germaine M, Glassock R, Goldfarb DS, Harris D, Hwang SJ, Imperial EB, Johansen KL, Kalantar-Zadeh K, Moist LM, Rayner B, Steiner R, Zuo L. Dialysis initiation: what's the rush? Semin Dial. 2013 Nov-Dec;26(6):6 — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | All-cause mortality: Proportion of patients who die from any cause | Proportion of patients who die from any cause during observation period. | From date of enrollment until the end of study, assessed up to 3 years | |
Primary | Acute nonfatal cerebro-cardiovascular events before dialysis initiation | Proportion of patients who suffer from acute nonfatal cerebro-cardiovascular events before dialysis initiation. Cerebro-cardiovascular events include acute myocardial infarction,acute coronary ischemia syndrome,acute heart failure, acute exacerbation of chronic heart failure ,severe arrhythmia, stroke, etc. |
From date of enrollment until the date of dialysis initiation, or the date of death from any cause,or the end of study, whichever came first, assessed up to 3 year | |
Primary | Acute nonfatal cerebro-cardiovascular events after dialysis initiation | Proportion of patients who suffer from acute nonfatal cerebro-cardiovascular events after dialysis initiation. Cerebro-cardiovascular events include acute myocardial infarction,acute coronary ischemia syndrome,acute heart failure, acute exacerbation of chronic heart failure ,severe arrhythmia, stroke, etc. |
From date of dialysis initiation until the date of death from any cause,or the end of study, whichever came first, assessed up to 3 year | |
Secondary | Hospitalization: Proportion of patients who are admitted to hospital | Proportion of patients who are admitted to hospital | From date of enrollment until the date of death from any cause,or the end of study, whichever came first, assessed up to 3 year | |
Secondary | Nutrition assessment | SGA assessment and serum albumin level are used to assess nutrition status | From date of enrollment until the date of death from any cause,or the end of study, whichever came first, assessed up to 3 years, performed every 3 months | |
Secondary | Patient reported outcome of quality of life | The short form health survey questionnaire 36 will be used. | From date of enrollment until the date of death from any cause,or the end of study, whichever came first, assessed up to 3 years, once every 3 months | |
Secondary | Complications of dialysis | Proportion of patients who suffer from dialysis complications including blood acess infection, thrombosis, hypotension, etc. | From date of dialysis initiation until the date of death from any cause,or the end of study, whichever came first, assessed up to 3 year | |
Secondary | Costs | All money patients and insurance agency spend on medical care related with CKD | From date of enrollment until the date of death from any cause,or the end of study, whichever came first, assessed up to 3 years, performed every 3 months | |
Secondary | Arteriovenous fistulas usage | Proportion of patients using arteriovenous fistulas as their blood access when dialysis initiation. The timing for preparing arteriovenous fistulas depends on the past GFR decline trajectory | From date of enrollment until the date of dialysis initiation, assessed up to 3 years | |
Secondary | Catheter usage | Proportion of patients using catheter as their blood access when dialysis initiation. | From date of enrollment until the date of dialysis initiation, assessed up to 3 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05491642 -
A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses
|
Phase 1 | |
Recruiting |
NCT06363097 -
Urinary Uromodulin, Dietary Sodium Intake and Ambulatory Blood Pressure in Patients With Chronic Kidney Disease
|
||
Terminated |
NCT04043026 -
The Effects of Renal Function and Atrial Fibrillation on Lipoproteins and Clot Structure/Function
|
||
Completed |
NCT05318014 -
Low-protein Formula Supplements in Chronic Kidney Disease
|
N/A | |
Active, not recruiting |
NCT06071065 -
Clinical Pharmacist Intervention on Medication Adherence and Clinical Outcomes in Chronic Kidney Disease Patients
|
N/A | |
Completed |
NCT02878317 -
Skin Autofluorescence as a Risk Marker in People Receiving Dialysis.
|
||
Not yet recruiting |
NCT06039254 -
Safety and Pharmacokinetics of HRS-1780 in Healthy Subjects and Subjects With Impaired Renal Function
|
Phase 1 | |
Recruiting |
NCT03160326 -
The QUALITY Vets Project: Muscle Quality and Kidney Disease
|
||
Completed |
NCT02888171 -
Impact of Ferric Citrate vs Ferrous Sulfate on Iron Parameters and Hemoglobin in Individuals With CKD and Iron Deficiency
|
N/A | |
Completed |
NCT02896309 -
The Effect of Correction of Metabolic Acidosis in CKD on Intrarenal RAS Activity
|
N/A | |
Completed |
NCT02756520 -
Observational Study on CKD Treatment With a Ketosteril Supplemented Protein-restricted Diet (Keto-024-CNI)
|
||
Completed |
NCT02875886 -
DD-study: Diet or Diuretics for Salt-sensitivity in Chronic Kidney Disease
|
Phase 4 | |
Completed |
NCT02836574 -
A Study of Renal Autologous Cell Therapy (REACT) in Type 2 Diabetics With Chronic Kidney Disease
|
Phase 2 | |
Withdrawn |
NCT02885545 -
The Strategy to Prevent Hemorrhage Associated With Anticoagulation in Renal Disease Management (STOP HARM) Trial
|
Phase 4 | |
Active, not recruiting |
NCT02483039 -
Nephrologist Follow-up Versus Usual Care After an Acute Kidney Injury Hospitalization
|
N/A | |
Completed |
NCT02369549 -
Micro-Particle Curcumin for the Treatment of Chronic Kidney Disease
|
Phase 3 | |
Completed |
NCT02992548 -
Effect of Pravastatin on Erythrocyte Membrane Fatty Acid Contents in Patients With Chronic Kidney Disease
|
Phase 4 | |
Terminated |
NCT02543177 -
Optimised Procedure in Patients With NSTEMI and CKD
|
N/A | |
Recruiting |
NCT02205944 -
Impact of Presurgical Exercise on Hemodialysis Fistula Outcomes
|
N/A | |
Active, not recruiting |
NCT02231138 -
Efficacy and Safety of Abelmoschus Manihot for Chronic Kidney Disease
|
Phase 4 |